ABCA7 deletion lowers age at onset of Alzheimer’s disease and interacts with APOE ε4 synergistically in African-ancestry populations

ABCA7 deletion lowers age at onset of Alzheimer’s disease and interacts with APOE ε4 synergistically in African-ancestry populations

The APOE gene is the strongest known genetic risk factor for Alzheimer disease (AD), first identified by Dr. Pericak-Vance and colleagues in 1993. The ε4 allele of APOE, a version of the gene, increases the risk of AD and is associated with an earlier age at onset, although its effect differs across ancestries.

Another important gene is ABCA7, particularly in individuals of African ancestry.  We previously identified a deletion, or missing segment of DNA, in ABCA7 that is specific to African-ancestry populations and is associated with an increased risk of AD. Because APOE and ABCA7 are both involved in lipid metabolism, which is important for brain health, we wanted to understand whether these two genetic factors might work together to influence when AD begins.

To answer this question, we studied 3,510 individuals of African ancestry, including African American and African participants from the DAWN Research project. Bringing these groups together allowed us to examine the effects of the ABCA7 deletion within a broader, global African-ancestry population.

We found that individuals who carried both one copy of the APOE ε4 allele and the ABCA7 deletion developed AD earlier than individuals who carried one copy of APOE ε4 but did not carry the deletion. The difference was approximately five years. These findings suggest that APOE and ABCA7 may interact to influence the age at onset of AD. Studying this type of gene-gene interaction can help us better understand the biological mechanisms that contribute to the disease.

The study also highlights the importance of global participation in AD research. Studying populations globally allows us to gain a more comprehensive view of the genetic architecture of AD and a better understanding of the biological mechanisms underlying the disease. By including participants from both the United States and Africa, this study provided a broader perspective on how genetic factors influence AD. Continued global collaboration will be essential for advancing diagnosis, prevention, and treatment approaches that can benefit people across all populations.

Akgun B, Gulyayev AV, Coker M, et al. ABCA7 deletion lowers age at onset of Alzheimer’s disease and interacts with APOE ε4 synergistically in African-ancestry populations. Alzheimers Dement. 2025 Aug;21(8):e70583. doi: 10.1002/alz.70583. PMID: 40832784; PMCID: PMC12365657.

Mining DNA for Alzheimer’s Secrets

Mining DNA for Alzheimer’s Secrets


By Josh Baxt

Researchers at the John P. Hussman Institute for Human Genomics (HIHG) at the University of Miami Miller School of Medicine are uncovering new insights into the genetic roots of Alzheimer’s disease, the most common form of dementia. Led by Anthony Griswold, Ph.D., and Brian Kunkle, Ph.D., M.P.H., the team is using advanced genome-wide association studies and whole-genome sequencing to identify genetic variations that influence risk and protection against the disease.

Their work casts a global net beyond populations of European ancestry to include groups from Africa, the Caribbean, and South America, revealing unique genetic markers and protective factors, such as variants in the APOEΣ4 gene. These discoveries are helping researchers better understand disease mechanisms and uncover new therapeutic targets.

The HIHG team is also advancing early detection efforts through innovative “liquid biopsy” techniques that identify Alzheimer’s biomarkers in blood plasma. This approach could allow for earlier diagnosis and more personalized treatment strategies.

“Every time we bring in a new population we’ve never studied before, we find new genetic markers,” said Dr. Griswold. “That’s going to help us develop diagnostic tests and medicines that could eventually help all people with Alzheimer’s.”

For the full story, click here.

Alz in the Hispanic Community

https://www.youtube.com/watch?v=ZyIH3eVroW0

 

The University of Miami Health System, through its Genomic Institute, is spearheading an initiative to increase Hispanic participation in Alzheimer’s research. The primary goal of this study is to identify genetic risks associated with the development of Alzheimer’s disease in the Hispanic-Latino population, which have not been extensively documented in medical literature.

Carolyn Banks’s story is not uncommon. As she noticed her older sister’s memory fading, her own brain health became a source of concern. This personal experience is reflective of a larger, more troubling trend observed in Miami-Dade County. The fear of memory loss, difficulty in recalling words, and names slipping away are signs that resonate with many in the community.

Despite Hispanics having the second highest risk of Alzheimer’s, they are only included in 1% of the studies conducted. Increasing their inclusion is not just about representation; it’s about improving access to medical resources and developing treatments specifically tailored for the community.

Jesús Carcases and his wife, who are caregivers for their 57-year-old daughter with Alzheimer’s, are participating in the study. They believe that involvement in such research is crucial for finding better outcomes. “This disease greatly affects families. We need to participate to seek better results,” says Carcases.

While there is currently no cure for Alzheimer’s, identifying specific human genome variants in this population can aid in creating preventive measures, especially for families at high risk of the disease. “Participating and helping this cause makes you feel good and happy,” adds Carcases.

For more information about Alzheimer’s studies or to participate, individuals can call 877-582-2788 or visit thedawnstudy.com.

Dream Spring, dedicated to transforming dreams into reality, believes that every dream deserves a chance. They are committed to changing lives and transforming communities through their support.

A Community’s Hope

In the bustling heart of Miami-Dade County, a silent yet pervasive threat looms – Alzheimer’s disease. With the county recording the highest prevalence of this neurodegenerative disorder in the United States, the University of Miami Health System (UHealth) is at the forefront of groundbreaking research. Spearheaded by Dr. Margaret Pericak-Vance, a renowned human geneticist, her team at the John P. Hussman Institute for Human Genomics, and leading investigators from Case Western University, Columbia University, and Wake Forest University, as well as investigators in Africa, UHealth is unraveling the mysteries of Alzheimer’s, particularly in diverse populations.

The Growing Concern:

Carolyn Banks’s story is not uncommon. As she noticed her older sister’s memory fading, her own brain health became a source of concern. This personal experience is reflective of a larger, more troubling trend observed in Miami-Dade County. The fear of memory loss, difficulty in recalling words, and names slipping away are signs that resonate with many in the community.

A Focus on Genetics and Diversity:

Dr. Pericak-Vance’s research is pivotal in understanding why certain populations are more susceptible to Alzheimer’s. Studies indicate that Hispanic and African Americans face a 1.5 to 2-fold increased risk compared to non-Hispanic Europeans. The key lies in genetic research which focuses on populations typically underrepresented in genetic research: individuals with African and Hispanic ancestry. By analyzing blood samples to sequence genes, the team at the Hussman Institute aims to uncover the genetic causes of Alzheimer’s and develop effective treatments and therapies that cater to all populations.

Understanding Genetic Variants:

The crux of the research involves identifying specific genetic variants that increase Alzheimer’s risk. “Everyone has these genes, but what does a particular variant or change do? How does it increase Alzheimer’s risk?” These questions drive the team’s research. Understanding the mechanism behind these genetic changes is crucial for developing targeted interventions.

The DAWN Project:

Central to this endeavor is the DAWN Alzheimer’s Research project, which will enroll 13,000 individuals over five years, including 4,000 Hispanic Latinos, 4,000 African Americans, and 5,000 Africans. This diverse study is vital in understanding Alzheimer’s in different race/ethnic groups.

Community Engagement and Participation:

Carolyn Banks’s participation in the research highlights the importance of community involvement. Activities involving memory exercises and social interaction are part of the study, emphasizing the role of mental and social stimulation in brain health. Carolyn’s engagement, driven by her desire to help others like her sister, underscores the need for community awareness and education in tackling Alzheimer’s.

Conclusion:

The University of Miami’s commitment to Alzheimer’s research is more than a scientific pursuit; it’s a beacon of hope for communities grappling with the disease. By focusing on genetic research and diverse participation, UHealth is not only advancing our understanding of Alzheimer’s but also fostering a sense of empowerment and solidarity among those affected. As Carolyn Banks and many others join this fight, their involvement echoes a powerful message – in the face of Alzheimer’s, no one stands alone.

 

Skip to content